Newsletter registration

By using our website, you are agreeing to cookies being stored and Google Analytics being used on your device in order to offer the best possible service. You can find more information on thishere.
Austria.
Where Your Profits Grow Sky High.

Johannes Kepler University of Linz: Injection against heart attacks

David Bernhard © JKU

Taking action quickly can help to save lives. Researchers at the Johannes Kepler University of Linz are now developing an injection with which emergency physicians can save about 20 percent of the patient’s heart muscle from dying off. The new drug has already been successfully tested in the laboratory.

In the case of a heart attack, part of the heart is cut off from the oxygen supply. The surrounding heart tissue is not fully supplied with ultimately first ties after some time. This issue can be saved thanks to the new development of Prof. David Bernhard, Head of the Center for Medical Research at Johannes Kepler University of Linz. He developed a substance named 5`-Methoxyleoligin. The special property of this substance is that it not only protects the insufficiently supplied heart issue from the effects of the heart attack but can also be administered intravenously. Up until now treatment of the heart could first take place in a hospital within the context of a surgical procedure. Methoxyleoligin is originally derived from the roots of the edelweiss but can be synthetically produced in the meantime. All in all, experts from six Austrian universities worked on the project for several years under the leadership of the University of Linz.

Share on Facebook Share on Facebook Share on Twitter Share on Twitter Share on Linkedin Share on Linkedin

Testimonials

Events

Meet us at events, seminars and trade shows - worldwide.

  • Research and Found Your Company in Austria

    29.01.2020 / 16:30 - 18:00, Zurich, Switzerland

  • New Year's Reception

    29.01.2020 / 18:00, Zurich, Switzerland

Austria Map

Find the perfect location for your company

Austria stands out due to its long-term reliable and stable conditions. These features are particularly important for a research-based company such as Boehringer Ingelheim. Furthermore, Vienna is a city with a good research infrastructure and a high quality of life, and is thus also an interesting place for highly qualified employees from Austria and abroad.

Boehringer Ingelheim

Logo
More testimonials

news from the business location Austria

Turbocharger for the business location

The new Austrian Federal Government is committed to strengthening the economy, as shown in its programme, and has incorporated numerous measures to enhance the viability of Austria as a business location.

The new research allowance in Germany – in competition with the Austrian research tax credit?

Companies carrying out research and development in Austria have the possibility to apply for research funding, namely the so-called research tax credit. In an international comparison, the Austrian research tax credit is a recipe for success and is designed to showcase and enhance the attractiveness of Austria as a research location. The successive increase in the research tax credit from the original level of three percent in 2002 to 14 percent at present has made a massive contribution to this success.

More news All blog posts